AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23043450 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrow CorAide left ventricular assist system (LVAS)
Number of subjects: 21
Study 21966064 — intervention group
Group type: EXPERIMENTAL
Intervention: ramelteon (8 mg)
Number of subjects: 30
Study 21966064 — intervention group
Group type: EXPERIMENTAL
Intervention: zopiclone (7.5 mg)
Number of subjects: 30
Study 21966064 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 19786427 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal salivary cotinine levels (SCLs) > or =20 ng/mL
Number of subjects: 714
Study 19786427 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal salivary cotinine levels (SCLs) > or =50 ng/mL
Number of subjects: 714
Study 19786427 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal salivary cotinine levels (SCLs) > or =100 ng/mL
Number of subjects: 714
Study 16679271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-head power injector using 0.6 mL/kg contrast flushed by 30 mL of saline solution (group D)
Number of subjects: 151
Study 16679271 — intervention group
Group type: COMPARATOR
Intervention: Single-head power injector using 1.0 mL/kg contrast only (group S)
Number of subjects: 151
Study 15385017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 120
Study 15385017 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 120
Study 15385017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Halothane (combined)
Number of subjects: 120
Study 15385017 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 120
Study 11253523 — intervention group
Group type: COMPARATOR
Intervention: Jet lavage
Number of subjects: 57
Study 9292481 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaR magnitudes presented at the onset of an inspiration or by interrupting an inspiration (n = 9)
Number of subjects: 15
Study 9292481 — intervention group
Group type: EXPERIMENTAL
Intervention: Three DeltaR magnitudes (n = 6)
Number of subjects: 15
Study 8512761 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 31
Study 8512761 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5-20 mg once daily)
Number of subjects: 31
Study 3566999 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery cannulation (group I)
Number of subjects: 46
Study 3566999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsalis pedis artery cannulation (group II)
Number of subjects: 46
Study 3566999 — intervention group
Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 46
Study 29088414 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education group (PEG)
Number of subjects: 120
Study 29088414 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provider group (CPG)
Number of subjects: 120
Study 29088414 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 120
Study 27854354 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO STOPS intervention involving community engagement and action plans
Number of subjects: 10
Study 27854354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific interventions)
Number of subjects: 10
Study 25433826 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple relationship education integrated in antenatal education
Number of subjects: 0
Study 21917562 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant healing
Number of subjects: 17
Study 21917562 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 20435569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 74
Study 20435569 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial AUC/MIC > 119
Number of subjects: 74
Study 20435569 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC/MIC < 176
Number of subjects: 74
Study 20435569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa
Number of subjects: 74
Study 18515735 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid (4 mg intravenously every 6 months)
Number of subjects: 1667
Study 18515735 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid
Number of subjects: 1667
Study 15811162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ome‐Mg 20 (20.6 mg omeprazole magnesium)
Number of subjects: 0
Study 15811162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ome‐Mg 10 (10.3 mg omeprazole magnesium)
Number of subjects: 0
Study 15811162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12026923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular teeth
Number of subjects: 0
Study 12026923 — intervention group
Group type: COMPARATOR
Intervention: Maxillary teeth
Number of subjects: 0
Study 10203078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support supplemented with key nutrients (Impact, Immun‐Aid)
Number of subjects: 1009
Study 10203078 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional support
Number of subjects: 1009
Study 8787952 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (2 IU) + Hex (2 micrograms/kg iv)
Number of subjects: 5
Study 8787952 — intervention group
Group type: COMPARATOR
Intervention: Saline + Hex (2 micrograms/kg iv)
Number of subjects: 5
Study 1668125 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day for three days
Number of subjects: 30
Study 1668125 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg acute dose
Number of subjects: 30
Study 6958483 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide administered three hours before challenge
Number of subjects: 12
Study 6958483 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide administered twice daily for one week before challenge
Number of subjects: 12
Study 6958483 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (one week's treatment)
Number of subjects: 12
Study 6958483 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three hours before challenge
Number of subjects: 12
Study 6958483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one week's treatment)
Number of subjects: 12
Study 31030867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 82
Study 31030867 — intervention group
Group type: COMPARATOR
Intervention: Active psychological treatment (control)
Number of subjects: 82
Study 29237686 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Heart Talk intervention
Number of subjects: 1300
Study 25670916 — intervention group
Group type: COMPARATOR
Intervention: Passive chair transfer
Number of subjects: 10
Study 25670916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting on the edge of the bed
Number of subjects: 10
Study 25670916 — intervention group
Group type: COMPARATOR
Intervention: Comparison of sitting on the edge of the bed vs passive chair transfer
Number of subjects: 10
Study 24323549 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL30 (30 ml kg(-1) crystalloid)
Number of subjects: 100
Study 24323549 — intervention group
Group type: COMPARATOR
Intervention: CSL10 (10 ml kg(-1) crystalloid)
Number of subjects: 100
Study 21695405 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach Imagery
Number of subjects: 182
Study 21695405 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach Imagery combined with Process Imagery
Number of subjects: 182
Study 19686479 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA)
Number of subjects: 414
Study 19686479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 414
Study 19686479 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 414
Study 19686479 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 414
Study 17538803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 281
Study 17538803 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus cream 1%
Number of subjects: 281
Study 14762857 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin combination therapy
Number of subjects: 119
Study 14762857 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon monotherapy
Number of subjects: 119
Study 11328902 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (ferrous sulphate 200 mg tds)
Number of subjects: 45
Study 11328902 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron (300 mg iron sucrose monthly)
Number of subjects: 45
Study 9308269 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia suggestion
Number of subjects: 0
Study 9308269 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 0
Study 9308269 — intervention group
Group type: EXPERIMENTAL
Intervention: Word memory task
Number of subjects: 0
Study 9308269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit-rotor task
Number of subjects: 0
Study 9308269 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control (minds wandering)
Number of subjects: 0
Study 8185690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine A (CSA) - initial dosage 2.5 mg/kg/day, maintenance dosage 3.6 mg/kg/day
Number of subjects: 44
Study 8185690 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) - initial dosage 300 mg/day, maintenance dosage 100 mg/day
Number of subjects: 44
Study 3358238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intramuscular streptomycin plus oral tetracycline over 14 days
Number of subjects: 37
Study 3358238 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day course of oral co-trimoxazole (trimethoprim-sulfamethoxazole)
Number of subjects: 37
Study 31135265 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard five-port technique with a fan-type liver retractor (Group A)
Number of subjects: 100
Study 31135265 — intervention group
Group type: COMPARATOR
Intervention: Four-port technique with liver retracted using a polypropylene suture (Group B)
Number of subjects: 100
Study 31135265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 28904247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 361
Study 28904247 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 361
Study 25886031 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 filtering facepiece respirators with filter resistive loads of 94.1 Pa - 119.6 Pa pressure
Number of subjects: 32
Study 25886031 — intervention group
Group type: COMPARATOR
Intervention: No intervention (without N95 respirators)
Number of subjects: 32
Study 24203808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral AcrySof ReSTOR +3.0 D toric IOLs (Models SND1T3, SND1T4, or SND1T5)
Number of subjects: 49
Study 21365126 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ITF2357 (givinostat)
Number of subjects: 0
Study 21365126 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ITF2357 (givinostat)
Number of subjects: 0
Study 21365126 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ITF2357 (givinostat)
Number of subjects: 0
Study 21365126 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ITF2357 (givinostat)
Number of subjects: 0
Study 21365126 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ITF2357 (givinostat)
Number of subjects: 0
Study 21365126 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of 50 or 100 mg ITF2357 (givinostat)
Number of subjects: 0
Study 19082653 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito 7.5 g/day
Number of subjects: 11
Study 19082653 — intervention group
Group type: COMPARATOR
Intervention: Control (without rikkunshito)
Number of subjects: 11
Study 17250926 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional meal context (meal condition)
Number of subjects: 0
Study 17250926 — intervention group
Group type: COMPARATOR
Intervention: Non-meal context (tasting session)
Number of subjects: 0
Study 17250926 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical meal context (preload)
Number of subjects: 0
Study 17250926 — intervention group
Group type: COMPARATOR
Intervention: Non-meal context (preload)
Number of subjects: 0
Study 15114302 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic papillary balloon dilation
Number of subjects: 32
Study 15114302 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy
Number of subjects: 32
Study 15114302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 12100048 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 1302
Study 12100048 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 1302
Study 12100048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1302
Study 12100048 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1302
Study 12100048 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 1302
Study 12100048 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Loratadine
Number of subjects: 1302
Study 9682339 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 0.1 ml of inactivated poliovirus vaccine (IPV) intradermally 8 weeks apart (group A)
Number of subjects: 78
Study 9682339 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of inactivated poliovirus vaccine (IPV) intradermally 4 weeks apart (group B)
Number of subjects: 78
Study 9682339 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants without pre-existing maternal antibody in both groups
Number of subjects: 78
Study 7940114 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 32 mg iv 1 hour prior to treatment +/‐ corticosteroids
Number of subjects: 10
Study 7940114 — intervention group
Group type: COMPARATOR
Intervention: prochlorperazine +/‐ corticosteroids
Number of subjects: 10
Study 2510140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1000 mg aspirin as lysine salt
Number of subjects: 18
Study 2510140 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 1000 mg aspirin as lysine salt
Number of subjects: 18
Study 2510140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1000 mg aspirin as lysine salt
Number of subjects: 18
Study 1096292 — intervention group
Group type: EXPERIMENTAL
Intervention: Human exogenous interferon (1 million units, intramuscularly, for 5-8 days)
Number of subjects: 37
Study 1096292 — intervention group
Group type: COMPARATOR
Intervention: Culture medium (control)
Number of subjects: 37
Study 31464460 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-breaks of varying durations and activities
Number of subjects: 232
Study 31464460 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-breaks
Number of subjects: 232
Study 30139553 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE program
Number of subjects: 404
Study 30139553 — intervention group
Group type: COMPARATOR
Intervention: Usual Community Care
Number of subjects: 404
Study 28068520 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week quadriceps strengthening program
Number of subjects: 97
Study 28068520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study 28068520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 97
Study 25963237 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG); 2 supervised group and 2 home exercise sessions/week
Number of subjects: 137
Study 25963237 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG); requested to maintain their physical activity
Number of subjects: 137
Study 23351405 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCC supplementation (3 g/d)
Number of subjects: 30
Study 23351405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 21173385 — intervention group
Group type: EXPERIMENTAL
Intervention: B.A.Bar dialogue training
Number of subjects: 18
Study 21173385 — intervention group
Group type: COMPARATOR
Intervention: Nonlinguistic training
Number of subjects: 18
Study 21141018 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia without sedation (Group A)
Number of subjects: 100
Study 21141018 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with sedation (Group B)
Number of subjects: 100
Study 17426620 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic neck pain patients
Number of subjects: 100
Study 17426620 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 17426620 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic neck pain patients and Control group
Number of subjects: 100
Study 15108976 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable ventilation (VV)
Number of subjects: 41
Study 15108976 — intervention group
Group type: COMPARATOR
Intervention: Control mode ventilation (CV)
Number of subjects: 41
Study 11170993 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SLPI concentrations (>100 ng/mL)
Number of subjects: 60
Study 11170993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SLPI concentrations (<100 ng/mL)
Number of subjects: 60
Study 11170993 — intervention group
Group type: COMPARATOR
Intervention: Vaginal fluid SLPI concentrations
Number of subjects: 60
Study 11170993 — intervention group
Group type: COMPARATOR
Intervention: Vaginal HIV‐1 concentrations
Number of subjects: 60
Study 7995992 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-3 vaccine strain
Number of subjects: 15
Study 7995992 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-14 vaccine strain
Number of subjects: 15
Study 7995992 — intervention group
Group type: COMPARATOR
Intervention: Peru-3 or Peru-5 vaccinees
Number of subjects: 15
Study 2921255 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 22
Study 2921255 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid resuscitation (control)
Number of subjects: 22
Study 170820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (50% of calories) during period IV
Number of subjects: 7
Study 170820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (50% of calories) during period III
Number of subjects: 7
Study 170820 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-free diet (70% fat and 30% protein) during period II
Number of subjects: 7
Study 31122846 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic reaming technique
Number of subjects: 131
Study 31122846 — intervention group
Group type: COMPARATOR
Intervention: Conventional reaming technique
Number of subjects: 131
Study 29178760 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing lysozyme
Number of subjects: 70
Study 29178760 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what control was used)
Number of subjects: 70
Study 24737786 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 487
Study 24737786 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (sulfasalazine+hydroxychloroquine)
Number of subjects: 487
Study 24737786 — intervention group
Group type: COMPARATOR
Intervention: Infliximab vs Conventional treatment
Number of subjects: 487
Study 22633663 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection and thrombus aspiration (DP-TA)
Number of subjects: 126
Study 22633663 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI (c-PCI)
Number of subjects: 126
Study 21590485 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (primary fixation)
Number of subjects: 95
Study 21590485 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 95
Study 18430574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Number of subjects: 392
Study 18430574 — intervention group
Group type: COMPARATOR
Intervention: Sodium Hyaluronate
Number of subjects: 392
Study 16847589 — intervention group
Group type: EXPERIMENTAL
Intervention: Model Development (MD) group
Number of subjects: 40
Study 16847589 — intervention group
Group type: EXPERIMENTAL
Intervention: Model Validation (MV) group
Number of subjects: 40
Study 16847589 — intervention group
Group type: COMPARATOR
Intervention: Other models tested
Number of subjects: 40
Study 16163534 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tyrosine and phenylalanine depletion (TPD)
Number of subjects: 14
Study 12514655 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin group (aspirin plus coumarins started 1 week before the procedure)
Number of subjects: 531
Study 12514655 — intervention group
Group type: COMPARATOR
Intervention: ASA group (aspirin alone)
Number of subjects: 531
Study 12514655 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal anticoagulation (defined as an international normalized ratio >70% of the follow‐up time in the target range)
Number of subjects: 531
Study 10362332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine
Number of subjects: 134
Study 10362332 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 134
Study 8847042 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (6 months)
Number of subjects: 19
Study 8847042 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus Interferon (6 months)
Number of subjects: 19
Study 2286796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic regional hyperthermia (HT) using BSD‐1000 HT system and annular phased array (AA) applicator or BSD‐2000 HT system and Sigma‐60 (S60) applicator
Number of subjects: 26
Study 2286796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic regional hyperthermia (HT)
Number of subjects: 26
Study 6270708 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH4-10 (Org O163) 30 mg
Number of subjects: 20
Study 6270708 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH4-9 analog (Org 2766) dosages of 0.05 mg, 0.5 mg, and 5 mg
Number of subjects: 20
Study 29679899 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of VLBW infants
Number of subjects: 403
Study 29679899 — intervention group
Group type: COMPARATOR
Intervention: Control group (parents of term infants)
Number of subjects: 403